Outcome of Lower-Risk Patients with Myelodysplastic Syndromes without 5Q Deletion after Failure of Erythropoiesis Stimulating Agents. (April 2017) - Park, S.; Hamel, J.F.; Toma, A.; Kelaidi, C.; Thepot, S.; Campelo Diez, M.; Santini, V.; Sekeres, M.; Balleari, E.; Kaivers, J.; Goetze, K.; Beyne-Rauzy, O.; et al.